News about genomics analysis tools including next generation sequencing, electrophoresis, PCR, and others
Congenica Expands in North America with Strategic Appointment Shikha O’Brien, Chief Business Officer Genomics Analysis Leader Appoints Dr Shikha O’Brien as Chief Business Officer 16th January 2017, Cambridge UK Congenica, a world leading developer of genome analysis and interpretation technologies, expands its operations in the US with the announcement that it has recruited Dr Shikha... Read more
HERCULES, Calif. — January 16, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during... Read more
MENLO PARK, Calif., and BEIJING, Jan. 16, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene Corporation, a leading provider of genomic and bioinformatic services, today announced that Novogene has agreed to purchase 10 Sequel™ Systems for whole genome sequencing, Iso-Seq™ annotation and targeted sequencing services.PacBio’s sequencing systems are based on its... Read more
MENLO PARK, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced that its Single Molecule, Real-Time (SMRT®) Sequencing technology will be featured in at least 57 podium presentations and 60 posters at the International Plant & Animal Genome (PAG) XXV Conference taking place January 14-18 in San Diego, California. From specialty beverage... Read more
SAN DIEGO and HERCULES, Calif. — January 9, 2017 — Illumina, Inc. (NASDAQ: ILMN) and Bio‑Rad Laboratories, Inc. (NYSE: BIO)(NYSE: BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers... Read more
Monday, January 9, 2017 MENLO PARK, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced a new version of chemistry (V2) and software (V4) for the Sequel™ System. The new release improves the system’s ability to support important applications such as structural variant detection and targeted sequencing—including metagenomics, minor... Read more
MENLO PARK, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced a new version of chemistry (V2) and software (V4) for the Sequel™ System. The new release improves the system’s ability to support important applications such as structural variant detection and targeted sequencing—including metagenomics, minor variant detection and isoform... Read more
Company CEO to update industry in presentation at the 35th Annual J.P. Morgan Healthcare Conference January 05, 2017 07:30 AM Eastern Standard Time MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–DNAnexus Inc., the global leader in genome informatics and data management, today announced two significant additions to the company’s executive leadership team. Brady Davis has joined the company as... Read more
STORY HIGHLIGHTS New Edico Genome bundle offers a pre-configured, out-of-the-box solution for rapid analysis and efficient storage of next-generation sequencing data. Available now, the solution allows for simple implementation for users while reducing storage costs, speeding analysis and maintaining high accuracy. Bundle enables analysis of a whole genome in as little as 22 minutes, which... Read more
AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. This is the third assay the FDA has cleared for use on the Luminex ARIES® Systems. The company has also... Read more